• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures In Human Peripheral Blood Mononuclear Cells

tetano

Editor, Senior Moderator
J Infect Dis. 2018 Dec 19. doi: 10.1093/infdis/jiy721. [Epub ahead of print]
[h=1]AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures In Human Peripheral Blood Mononuclear Cells.[/h] Howard LM[SUP]1[/SUP], Goll JB[SUP]2[/SUP], Jensen TL[SUP]2[/SUP], Hoek KL[SUP]3[/SUP], Prasad N[SUP]4[/SUP], Gelber CE[SUP]2[/SUP], Levy SE[SUP]4[/SUP], Joyce S[SUP]3,[/SUP][SUP]5[/SUP], Link AJ[SUP]3,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Creech CB[SUP]1[/SUP], Edwards KM[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]Background:[/h] Adjuvant System 03 (AS03) markedly enhances responses to influenza A/H5N1 vaccines, but the mechanisms of this enhancement are incompletely understood.
[h=4]Methods:[/h] Using RNA-Seq on peripheral blood mononuclear cells (PBMC) from AS03-adjuvanted and unadjuvanted inactivated H5N1 vaccine recipients, we identified differentially-expressed genes, enriched pathways, and genes that correlated with serologic responses. We compared bulk PBMC findings with our previously published assessments of flow-sorted immune cell types.
[h=4]Results:[/h] AS03-adjuvanted vaccine induced the strongest differential signals day 1 post-vaccination, activating multiple innate immune pathways including interferon and JAK-STAT signaling, FcγR-mediated phagocytosis, and antigen processing/presentation. Changes in signal transduction and immunoglobulin genes predicted peak hemagglutinin inhibition (HAI) titers. Compared to individual immune cell types, activated PBMC genes and pathways were most similar to innate immune cells. However, several pathways were unique to PBMC, and several pathways identified in individual cell types were absent in PBMC.
[h=4]Conclusions:[/h] Transcriptomic analysis of PBMC after AS03-adjuvanted H5N1 vaccination revealed early activation of innate immune signaling, including a 5-8-fold up-regulation of FcγR1A/1B/1C genes. Several early gene responses were correlated with HAI titer, indicating links with the adaptive immune response. While PBMC and cell-specific results shared key innate immune signals, unique signals were identified by both approaches.


PMID: 30566602 DOI: 10.1093/infdis/jiy721
 
Back
Top Bottom